A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 2214
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PBPK
Long Form : physiologically based pharmacokinetic
No. Year Title Co-occurring Abbreviation
2022 Comparison of tissue abundance of non-cytochrome P450 drug metabolizing enzymes by quantitative proteomics between humans and laboratory animal species. AOX, CES1, DMEs, SULT1B1
2021 A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development. ---
2021 A comprehensive review on non-clinical methods to study transfer of medication into breast milk - A contribution from the ConcePTION project. IVIVE
2021 A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. ARV, NHPs
2021 A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions. CYP3A4, DDIs
2021 A latent variable approach to account for correlated inputs in global sensitivity analysis. GSA
2021 A minimal physiologically based pharmacokinetic model for high-dose methotrexate. HD-MTX
2021 A Model Template Approach for Rapid Evaluation and Application of Physiologically Based Pharmacokinetic Models for Use in Human Health Risk Assessments: A Case Study on Per- and Polyfluoroalkyl Substances. ---
2021 A Novel Experimental and Theoretical Method for Estimating Albumin-Mediated Hepatic Uptake Based on the Albumin Binding Fraction in Plasma and Human PK Prediction Using a Physiologically-Based Pharmacokinetic Approach. PK
10  2021 A Novel Method for Predicting the Human Inherent Clearance and Its Application in the Study of the Pharmacokinetics and Drug-Drug Interaction between Azidothymidine and Fluconazole Mediated by UGT Enzyme. AZT, DDI, FCZ, PK, QSAR, UGT
11  2021 A PBPK model describing the pharmacokinetics of γ-HBCD exposure in mice. HBCD
12  2021 A Physiological-Based Pharmacokinetic Model For The Broad Spectrum Antimicrobial Zinc Pyrithione: II. Dermal Absorption And Dosimetry In The Rat. AUC, PT, ZnPT
13  2021 A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors. NETs, SSTR
14  2021 A physiologically based pharmacokinetic analysis to predict the pharmacokinetics of intravenous isavuconazole in patients with or without hepatic impairment. AUC, CL, ISA, PK
15  2021 A Physiologically Based Pharmacokinetic and Drug-Drug Interaction Model for the CB2 Agonist Lenabasum. AUC, CB2, SAD
16  2021 A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice. 212Pb-SSTA, ADC, alpha-PRRT
17  2021 A Physiologically Based Pharmacokinetic Model for Predicting Diazepam Pharmacokinetics after Intravenous, Oral, Intranasal, and Rectal Applications. AFE, PK
18  2021 A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children. PK
19  2021 A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function. AKI, DCD, DGF, IL-18, SAEs
20  2021 A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal antibodies to Advance Bamlanivimab into a First-in-Human Clinical Trial. COVID-19, mAb, SARS-CoV-2
21  2021 A rapid dynamic in vivo near-infrared fluorescence imaging assay to track lung vascular permeability after acute radiation injury. ICG, NIR, PS
22  2021 A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. NOWS, PK
23  2021 A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators. DDIs, OCTs, PMAT
24  2021 A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in Rats. ADCs, PKs, TAT
25  2021 An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease. Mpro
26  2021 An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. COVID-19, FDA, PK
27  2021 An Updated In Silico Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats. ---
28  2021 Antifungal Drugs TDM: Trends and Update. AF, DDI, ISZ, MIC, TDM
29  2021 Application of a dual mechanistic approach to support bilastine dose selection for older adults. PKs
30  2021 Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys. CP-I, OATP, RIF
31  2021 Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism. CA-VTE, DDDIs, MBI, OAT3, PKIs
32  2021 Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization. AUC, CYP3A4
33  2021 Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib. DDI, VEGFR
34  2021 Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment. ESRD, FDA, HAP, MCS, PK, RI, TBW
35  2021 Application of physiologically based pharmacokinetic models to promote the development of veterinary drugs with high efficacy and safety. VDs
36  2021 Apply a Physiologically Based Pharmacokinetic Model to Promote the Development of Enrofloxacin Granules: Predict Withdrawal Interval and Toxicity Dose. ENR
37  2021 Artemisinin Cocrystals for Bioavailability Enhancement. Part 2: In Vivo Bioavailability and Physiologically Based Pharmacokinetic Modeling. ART, ART-ORC, AUC, LC-HRMS, PK
38  2021 Assessment of drug-drug interaction and optimization in capecitabine and irinotecan combination regimen using a physiologically based pharmacokinetic model. 5-FU, CES
39  2021 Assessment of the Kochak-Benet Equation for Hepatic Clearance for the Parallel-Tube Model: Relevance of Classic Clearance Concepts in PK and PBPK. PK, PTM
40  2021 Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations. PK
41  2021 Bayesian population physiologically-based pharmacokinetic model for robustness evaluation of withdrawal time in tilapia aquaculture administrated to florfenicol. MCMC
42  2021 Bayesian Refinement of the Permeability-Limited Physiologically Based Pharmacokinetic Model for Perfluorooctanoic Acid in Male Rats. MCMC, PFOA
43  2021 Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions. CP-I, DDIs, OATP, PKs
44  2021 Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs. API, CQAs, NDA
45  2021 Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations. EMs, PMs
46  2021 Bridging the gap between in silico and in vivo by modeling opioid disposition in a kidney proximal tubule microphysiological system. CKD, CLR, HUVEC, M6G, PTEC, VPT-MPS
47  2021 Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling. AUCs
48  2021 Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development. AAG, ARV, P1026s
49  2021 Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate. Sul
50  2021 Closed-loop trans-skull ultrasound hyperthermia leads to improved drug delivery from thermosensitive drugs and promotes changes in vascular transport dynamics in brain tumors. DCE-MRI, MRgFUS, MRgFUS, TSL-Dox
51  2021 Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring. ---
52  2021 Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague. PopPK
53  2021 Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator. CYP3A, DDI
54  2021 Computational pharmaceutics - A new paradigm of drug delivery. NMEs
55  2021 Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide. BCRP, DDIs, MRP4, OATP2B1, OATs, P-gp, PK
56  2021 Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity. ADMET, MIDD
57  2021 Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. ATS, PK
58  2021 Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective. IQ, IWG
59  2021 Cytochrome P450-Mediated Metabolism and CYP Inhibition for the Synthetic Peroxide Antimalarial OZ439. ---
60  2021 Data-driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment. PK
61  2021 Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations. DDIs
62  2021 Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism. NTRK, ROS1
63  2021 Development and Application of an Interactive Physiologically Based Pharmacokinetic (iPBPK) Model to Predict Oxytetracycline Tissue Distribution and Withdrawal Intervals in Market-Age Sheep and Goats. FARAD, iPBPK, iPBPK, OTC
64  2021 Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients. PK
65  2021 Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug-drug interaction in healthy adults and its extrapolation to virtual chronic heart failure patients for dose optimization. ADME, mDDIs
66  2021 Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases. CHF, CKD, PK
67  2021 Development and Verification of a Linked Delta 9-THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women. 11-OH-THC, AUC, THC
68  2021 Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency. PK
69  2021 Development of a Gestational and Lactational Physiologically Based Pharmacokinetic (PBPK) Model for Perfluorooctane Sulfonate (PFOS) in Rats and Humans and Its Implications in the Derivation of Health-Based Toxicity Values. EPA, HEDs, PFAS, PFOS
70  2021 Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients. HCQ
71  2021 Development of a Physiologically Based Pharmacokinetic Model of Mitragynine, Psychoactive Alkaloid in Kratom (Mitragyna Speciosa Korth.), In Rats and Humans. BCRP, CYP3A4
72  2021 Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways. AUC, CL, PK
73  2021 Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans. Fa, GERD, P-CAB, PPIs
74  2021 Development of Physiologically Based Pharmacokinetic Model for Pregabalin to Predict the Pharmacokinetics in Pediatric Patients with Renal Impairment and Adjust Dosage Regimens: PBPK Model of Pregabalin in Pediatric Patients with Renal Impairment. PGB, PK, RI
75  2021 Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound? CYP3A4, DAK, P-gp
76  2021 Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling. AUCs, MIC
77  2021 Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach. ---
78  2021 Dosing Regimen Prediction and Confirmation with Rivaroxaban for Thromboprophylaxis in Children after the Fontan Procedure: Insights from the Phase III UNIVERSE Study. PK
79  2021 Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling Approach. DDIs, DZP, KOR, MD, MM-PBSA, MOR, OXY, PD, PK
80  2021 Elucidation of Metabolic and Disposition Pathways for Maribavir in Nonhuman Primates through Mass Balance and Semi-Physiologically Based Modeling Approaches. BDC, EHR, semi-PBPK
81  2021 Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs). UGTs
82  2021 Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. CLR, PopPK
83  2021 Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models. ASBT, DDI, NTCP, OAT, OATP
84  2021 Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route. BUP-XR, DDIs, OUD, PK
85  2021 Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model. CIs, DDI, OM, PK
86  2021 Evaluation of Pharmacokinetic Drug-Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches. DDIs
87  2021 Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups. BCS, GET
88  2021 Evaluation of Quantitative Structure Property Relationship Algorithms for Predicting Plasma Protein Binding in Humans. fup, MAE, QSPR, RPE
89  2021 Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach. DDI, FDA, P-gp
90  2021 Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin. DDI
91  2021 Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery. APA, LHS, PL
92  2021 Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients. ---
93  2021 Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam. ---
94  2021 Food constituent- and herb-drug interactions in oncology: Influence of quantitative modelling on Drug labelling. FC-DIs, SJW
95  2021 Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights. ECF
96  2021 Health Effects of Naphthalene Exposure: A Systematic Evidence Map and Analysis of Potential Considerations for Dose-Response Evaluation. LOAELs, PECO
97  2021 Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Gottingen Minipig: Pivotal Data for PBPK Modeling. GD, PND
98  2021 Hepatic Scaling Factors for In Vitro-In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis. CPPGL, IVIVE, MPPGL
99  2021 Hepatotoxicological potential of P-toluic acid in humanised-liver mice investigated using simplified physiologically based pharmacokinetic models. ---
100  2021 Human biomonitoring initiative (HBM4EU): Human biomonitoring guidance values (HBM-GVs) derived for bisphenol A. BPA, BPA-G, BPA-S, ECHA, EFSA, HBM-GVs, QA, QC, t-TDI